ConductScience.org, home

Paper41899088

Heterogeneity Analysis of HBeAg-Positive Chronic Hepatitis B Patients with Ultra-High Viral Load (HBV DNA ≥ 7.0 log10 IU/mL).

Li G and 3 others. J Clin Med, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Heterogeneity Analysis of HBeAg-Positive Chronic Hepatitis B Patients with Ultra-High Viral Load (HBV DNA ≥ 7.0 log10 IU/mL). Papers, record 41899088. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41899088

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Heterogeneity Analysis of HBeAg-Positive Chronic Hepatitis B Patients with Ultra-High Viral Load (HBV DNA ≥ 7.0 log10 IU/mL).
PubMed
Journal
J Clin Med
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Li GGuifeng
2Ren RRong
3Liu JJie
4Li JJia

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
MX202508NovoMu Research Funding, Chinese Foudation For Hepatitis Prevention and ControlPubMed
Grant No.TJYXZDXK-3-019BFunded by Tianjin Key Medical Discipline Construction ProjectPubMed

Source PubMed

Download CSV of grants

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126563120Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Hepatol Int2016https://conductscience.org/library/papers/26563120PubMed
236972391What will it take to cure hepatitis B?Hepatol Commun2023https://conductscience.org/library/papers/36972391PubMed
337179582Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.World J Gastroenterol2023https://conductscience.org/library/papers/37179582PubMed
439983746Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2025https://conductscience.org/library/papers/39983746PubMed
536603573Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase.Clin Mol Hepatol2023https://conductscience.org/library/papers/36603573PubMed
641179714Gray zone and the need for expansion in chronic hepatitis B: From theory to clinical practice.World J Hepatol2025https://conductscience.org/library/papers/41179714PubMed
733517606Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact.Clin Mol Hepatol2021https://conductscience.org/library/papers/33517606PubMed
836936922Abnormally primed CD8 T cells: The Achilles' heel of CHB.Front Immunol2023https://conductscience.org/library/papers/36936922PubMed
941151792EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection.Gut2026https://conductscience.org/library/papers/41151792PubMed
1041233830Significant histologic alterations in untreated chronic hepatitis B children: a meta-analysis.BMC Infect Dis2025https://conductscience.org/library/papers/41233830PubMed
1125911335EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.J Hepatol2015https://conductscience.org/library/papers/25911335PubMed
1238550589High normal alanine aminotransferase is an indicator for better response to antiviral therapy in chronic hepatitis B.Front Immunol2024https://conductscience.org/library/papers/38550589PubMed
1336028208Liver histology of treatment-naïve children with chronic hepatitis B virus infection in Shanghai China.Int J Infect Dis2022https://conductscience.org/library/papers/36028208PubMed
1422916211High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B.PLoS One2012https://conductscience.org/library/papers/22916211PubMed
1524733569The role of HBsAg levels in the current management of chronic HBV infection.Ann Gastroenterol2014https://conductscience.org/library/papers/24733569PubMed
1617928090The clinical significance of persistently normal ALT in chronic hepatitis B infection.J Hepatol2007https://conductscience.org/library/papers/17928090PubMed
1738206209Histological features of chronic hepatitis B patients with normal alanine aminotransferase according to different criteria.Hepatol Commun2024https://conductscience.org/library/papers/38206209PubMed
1838987588A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection.Nature2024https://conductscience.org/library/papers/38987588PubMed
1936324235Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone.Aliment Pharmacol Ther2023https://conductscience.org/library/papers/36324235PubMed
2033288393Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B.Eur J Intern Med2021https://conductscience.org/library/papers/33288393PubMed

See all 35 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41899088

GET https://conductscience.org/api/papers/v1/41899088/references?page=2